<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34b8eaa6-bab6-a452-e063-6394a90aa461"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CAMCEVI 
 <sup>Â®</sup>safely and effectively. See full prescribing information for CAMCEVI.
 <br/>
      <br/>
      <content styleCode="bold">CAMCEVI (leuprolide) injectable emulsion, for subcutaneous use
  <br/>
Initial U.S. Approval: 2021
 </content>
   </title>
   <effectiveTime value="20250509"/>
   <setId root="cbff25e5-6fe8-4e44-b10a-8397b3349905"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="079636487"/>
            <name>Accord BioPharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="273960691"/>
                        <name> Fareva Pau</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69448-023" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69448-023" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34b91fe2-4498-ba57-e063-6394a90a38e1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250509"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69448-023" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CAMCEVI</name>
                        <formCode code="C42914" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, EMULSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEUPROLIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="184"/>
                              <denominator unit="g" value="0.37"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="459TN2L5F5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYLACTIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="136"/>
                              <denominator unit="g" value="0.37"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JR9CE63FPM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPYRROLIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="42"/>
                              <denominator unit="g" value="0.37"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8E3C3C493W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEUPROLIDE MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="EFY6W0M8TG" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEUPROLIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.37" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="69448-023-63" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250519"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250519"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_ae60cfcf-c8ea-44e6-9c21-004c0d6662ce">
               <id root="2ef88b24-e859-13fa-e063-6294a90ad698"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dosage and Administration (
 
    <linkHtml href="#ss2.2">2.2</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 02/2025

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ss1">
               <id root="2ef88b24-e85a-13fa-e063-6294a90ad698"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.</paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ss2">
               <id root="2ef88b24-e85b-13fa-e063-6294a90ad698"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20240319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>See Full Prescribing Information for instructions on the preparation and administration of the injectable emulsion in a pre-filled syringe. (
  
     <linkHtml href="#ss2">2</linkHtml>)
 
    </item>
                           <item>Recommended Dosage: 42 mg subcutaneously every 6 months. (
  
     <linkHtml href="#ss2">2</linkHtml>)
 
    </item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ss2.1">
                     <id root="2ef88b24-e85c-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dose of CAMCEVI is 42 mg administered subcutaneously once every 6 months.</paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
               <component>
                  <section ID="ss2.2">
                     <id root="2ef88b24-e85d-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Preparation and Administration</title>
                     <text>
                        <paragraph>CAMCEVI must be administered by a healthcare provider.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Important:</content>Read the instructions completely before you administer Camcevi for the first time. Do NOT substitute any of the components from the kit for administration.

  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">CAMCEVI is packaged in a blister in the kit. Check to make sure the kit contains:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="xmChange">One sterile, single-dose pre-filled syringe with plunger rod and backstop</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">One sterile 18-gauge SurGuardÂ®3 safety needle, 5/8-inch needle</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Prescribing Information</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">Follow the detailed instructions to ensure correct preparation of CAMCEVI prior to administration:</content>
                        </paragraph>
                        <table>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 1 
     <br/>
                                    <br/>  Remove CAMCEVI kit from refrigerator. 
     <br/>
                                    <br/>  Keep the contents in their original, sealed blister carton and allow to sit at room temperature for 30 minutes before use. 
     <br/>
                                    <br/>  Return to refrigerator after 30 minutes if not used.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="Lacbe49c3-c83e-4a53-893c-26afca70e38e"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 2 
     <br/>
                                    <br/>  On a clean, dry surface, open carton and remove the contents. Examine all contents of the package. Do not use if any component is damaged. 
     <br/>
                                    <br/>  Check the expiration date on the syringe. Do not use if the expiration date has passed. 
     <br/>
                                    <br/>  The use of gloves is recommended during syringe assembly and administration.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="L452162f4-fd58-4bd8-a045-c23819adc331"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 3 
     <br/>
                                    <br/>  Remove pre-filled syringe (A) from the blister tray and open the safety needle (B) package by peeling back the paper tab. 
     <br/>
                                    <br/>  The safety needle (B) package is located beneath the blister tray. 
     <br/>
                                    <br/>  Visually inspect the syringe for particulate matter prior to administration. The emulsion should appear off-white to pale yellow, viscous, and opalescent. Do not use if particulate matter is observed prior to administration.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="Lb9b193eb-5c24-4c76-af6a-4278ba48de8b"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>STEP 4 
      <br/>
                                       <br/>  Remove the gray cap from the syringe (A). 
      <br/>
                                       <br/>  Attach the needle (B) to the end of the syringe (A) by gently screwing clockwise with approximately a three-quarter turn until the needle is secure .
     
      <content styleCode="bold">Do not overtighten, as the needle hub may become damaged resulting in leakage of the product during injection. The safety sheath may also be damaged if the needle is overtightened onto the syringe.</content>
                                       <br/>
                                       <br/>  See figure of assembled pre-filled syringe below.
    
     </paragraph>
                                    <paragraph>
                                       <renderMultiMedia referencedObject="Lf3bf6269-eefc-46f8-81d0-38f167830383"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="Led48f18f-bd42-4ea6-8224-c7223a193ee5"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 5 
     <br/>
                                    <br/>  Choose an injection site on the upper- or mid-abdominal area with sufficient soft or loose subcutaneous tissue that has not recently been used. 
     <br/>
                                    <br/>  Clean the injection site with an alcohol swab. 
     <br/>
                                    <br/>  Do
    
     <content styleCode="bold">NOT</content>inject in areas with brawny or fibrous subcutaneous tissue or locations that can be rubbed or compressed (i.e., with a belt or clothing waistband). In addition, avoid applying heat directly to the site of Camcevi injection.
   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="L75989179-3299-42bd-92ae-51ffd5ee50a9"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 6 
     <br/>
                                    <br/>  (1) Move the safety sheath away from the needle and towards the syringe and (2) remove the clear needle cover immediately before injection. 
     <br/>
                                    <br/>
                                    <content styleCode="bold">Note:</content>Should the needle hub appear to be damaged, or leak, the product should NOT be used. The damaged needle should NOT be replaced and the product should NOT be injected. In the event of damage to the needle hub, use a new replacement CAMCEVI kit.
   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="L71590ff1-8957-413d-b37c-cd308ba6946d"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 7 
     <br/>
                                    <br/>  Use standard aseptic technique when performing the injection. 
     <br/>
                                    <br/>  Grab and bunch the skin around the injection site with one hand. 
     <br/>
                                    <br/>  Insert the needle at a 90Â° angle to the skin surface, and then release the bunched skin.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 8 
     <br/>
                                    <br/>  Inject the full contents of the syringe with a slow and steady push on the plunger, and then withdraw the needle at the same 90Â° angle used for insertion.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <renderMultiMedia referencedObject="L79e01922-3868-49b8-96f0-ca1998bee6b8"/>
                                 </td>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 9 
     <br/>
                                    <br/>  Immediately following the withdrawal of the needle, activate the safety sheath using a finger/thumb or flat surface and push until it completely covers the needle tip and locks into place. 
     <br/>
                                    <br/>  An audible and tactile âclickâ verifies a locked position. 
     <br/>
                                    <br/>  Check to confirm the safety sheath is fully engaged.
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td colspan="2" styleCode="Botrule Lrule Rrule Toprule">STEP 10 
     <br/>
                                    <br/>  After use, discard all components safely in a suitable sharps container. Dispose of the syringe and contaminated products according to local regulations/procedures.
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20240319"/>
                     <component>
                        <observationMedia ID="Lacbe49c3-c83e-4a53-893c-26afca70e38e">
                           <text>camcevi-inj-image-2-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-2-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L452162f4-fd58-4bd8-a045-c23819adc331">
                           <text>camcevi-inj-image-3-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-3-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Lb9b193eb-5c24-4c76-af6a-4278ba48de8b">
                           <text>camcevi-inj-image-4-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-4-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Lf3bf6269-eefc-46f8-81d0-38f167830383">
                           <text>camcevi-inj-image-9-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-9-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Led48f18f-bd42-4ea6-8224-c7223a193ee5">
                           <text>camcevi-inj-image-5-terumo-needle.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-5-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L75989179-3299-42bd-92ae-51ffd5ee50a9">
                           <text>camcevi-inj-image-6-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-6-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L71590ff1-8957-413d-b37c-cd308ba6946d">
                           <text>camcevi-inj-image-7-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-7-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L79e01922-3868-49b8-96f0-ca1998bee6b8">
                           <text>camcevi-inj-image-8-terumo-needle</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="camcevi-inj-image-8-terumo-needle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss3">
               <id root="2ef88b24-e85e-13fa-e063-6294a90ad698"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injectable emulsion: 42 mg leuprolide (equivalent to approximately 48 mg leuprolide mesylate) as a sterile, off-white to pale yellow, viscous, and opalescent emulsion in a single-dose, pre-filled syringe for subcutaneous injection.</paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Injectable emulsion: 42 mg (
  
     <linkHtml href="#ss3">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ss4">
               <id root="2ef88b24-e85f-13fa-e063-6294a90ad698"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>CAMCEVI is contraindicated in patients known to be hypersensitive to GnRH, GnRH agonist analogs, or any of the excipients in CAMCEVI. Anaphylactic reactions to GnRH agonist analogs have been reported in the medical literature.</paragraph>
               </text>
               <effectiveTime value="20240318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI. (
  
     <linkHtml href="#ss4">4</linkHtml>)
 
    </item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ss5">
               <id root="2ef88b24-e860-13fa-e063-6294a90ad698"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20240318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tumor Flare: Transient worsening of bone pain, uretral obstruction, spinal cord compression, or the occurrence of additional signs and symptoms of prostate cancer may develop during the first few weeks of treatment. Monitor patients closely and manage symptoms. (
  
     <linkHtml href="#LINK_9c9c8cfa-504a-48ff-8f91-c21c4d7dfa17">5.1</linkHtml>)
 
    </item>
                           <item>Hyperglycemia and Diabetes: Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose levels and manage according to current clinical practice. (
  
     <linkHtml href="#LINK_06caf897-68c2-46c9-bd87-bb600e7eaeda">5.2</linkHtml>)
 
    </item>
                           <item>Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in men receiving GnRH agonists. Monitor for cardiovascular disease and manage according to current clinical practice. (
  
     <linkHtml href="#LINK_9fc994f7-6a63-47eb-8b23-a3c3041f2290">5.3</linkHtml>)
 
    </item>
                           <item>QT/QTc Prolongation: Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes. (
  
     <linkHtml href="#ss5.7">5.4</linkHtml>)
 
    </item>
                           <item>Convulsions: Manage convulsions according to the current clinical practice. (
  
     <linkHtml href="#LINK_9fc994f7-6a63-47eb-8b23-a3c3041f2295">5.5</linkHtml>)
 
    </item>
                           <item>Embryo-Fetal Toxicity: CAMCEVI may cause fetal harm. (
  
     <linkHtml href="#LINK_9fc994f7-6a63-47eb-8b23-a3c3041f2292">5.7</linkHtml>,
  
     <linkHtml href="#LINK_9fc994f7-6a63-47eb-8b23-a3c3041f2281">8.1</linkHtml>)
 
    </item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ss5.1">
                     <id root="2ef88b24-e861-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Tumor Flare</title>
                     <text>
                        <paragraph>CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment, declining thereafter to baseline levels or below by the end of the second week of treatment. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may develop during the first few weeks of CAMCEVI treatment. Patients treated with CAMCEVI may experience a temporary increase in bone pain, which can be managed symptomatically.</paragraph>
                        <paragraph>Cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.</paragraph>
                        <paragraph>Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss5.2">
                     <id root="2ef88b24-e862-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hyperglycemia and Diabetes</title>
                     <text>
                        <paragraph>Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent the development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss5.3">
                     <id root="2ef88b24-e863-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cardiovascular Diseases</title>
                     <text>
                        <paragraph>Increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss5.4">
                     <id root="2ef88b24-e864-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 QT/QTc Prolongation</title>
                     <text>
                        <paragraph>Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss5.5">
                     <id root="2ef88b24-e865-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Convulsions</title>
                     <text>
                        <paragraph>Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#ss6.2">6.2</linkHtml>)].
 
  </content>Manage patients receiving a GnRH agonist who experience convulsions according to current clinical practice.

 </paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss5.6">
                     <id root="2ef88b24-e866-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Laboratory Tests</title>
                     <text>
                        <paragraph>Monitor serum levels of testosterone following injection of CAMCEVI. In the majority of patients treated with CAMCEVI, testosterone levels increased above baseline during the first week, and then declined thereafter to castration levels (&lt;50 ng/dL) within 4 weeks
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#ss14">14</linkHtml>) and Adverse Reactions (
  
   <linkHtml href="#ss6">6</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss5.7">
                     <id root="2ef88b24-e867-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings in animal studies and mechanism of action, CAMCEVI can cause fetal harm when administered to a pregnant woman. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus
 
  <content styleCode="italics">[see Use in Specific Population (
  
   <linkHtml href="#ss8.1">8.1</linkHtml>), Clinical Pharmacology (
  
   <linkHtml href="#ss12.1">12.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss6">
               <id root="2ef88b24-e868-13fa-e063-6294a90ad698"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Tumor Flare
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ss5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Hyperglycemia and Diabetes
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ss5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Cardiovascular Diseases
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ss5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>QT/QTc Prolongation
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ss5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                     <item>Convulsions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#ss5.5">Warnings and Precautions (5.5)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common (â¥5%) adverse reactions were hot flushes, hypertension, injection site reactions, fatigue, upper respiratory tract infections, musculoskeletal pain, pain in extremity, arthralgia, micturition urgency, nocturia, and dizziness. (
 
    <linkHtml href="#ss6.1">6.1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or</content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ss6.1">
                     <id root="2ef88b24-e869-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FP01C-13-001</content>
                        </paragraph>
                        <paragraph>The safety of CAMCEVI was evaluated in an open-label, single-arm, international clinical trial (FP01C-13-001) in patients with advanced prostate cancer. Patients received CAMCEVI administered subcutaneously at a dose of 42 mg on Day 0 and Day 168. Of 137 patients enrolled, 93% received both doses of CAMCEVI.</paragraph>
                        <paragraph>Serious adverse reactions occurred in 15% of patients who received CAMCEVI, including 1% of patients who experienced subdural hematoma. Fatal adverse reactions occurred in 2% of patients, including cerebrovascular accident (0.7%) and pulmonary embolism (0.7%).</paragraph>
                        <paragraph>The most common adverse reactions (â¥10%) occurring during a median follow-up duration of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.</paragraph>
                        <paragraph>Table 1 summarizes the adverse reactions in FP01C-13-001.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Table 1. Adverse Reactions Occurring in â¥5% of CAMCEVI in Advanced Prostate Cancer Patients - FP01C-13-001</content>
                        </paragraph>
                        <table width="70%">
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </content>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="underline">
                                       <content styleCode="bold">CAMCEVI 
       <br/>  N=137
      </content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="underline">
                                       <content styleCode="bold">All Grades 
       <br/>  (%)
      </content>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="underline">
                                       <content styleCode="bold">Grade 3-4 
       <br/>  (%)
      </content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">Vascular disorders</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Hot flushes
    
     <sup>a</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">50</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Hypertension
    
     <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">15</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">General disorders and administration site conditions</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Injection site reactions
    
     <sup>c</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">11</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Fatigue
    
     <sup>d</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">10</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">Infections and infestations</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â  Upper respiratory tract infection
    
     <sup>e</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">11</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">Musculoskeletal and connective tissue disorders</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â  Musculoskeletal pain
    
     <sup>f</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">11</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â  Pain in extremity</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">10</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Arthralgia</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">7</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">Renal and urinary disorders</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â  Micturition urgency
    
     <sup>g</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">6</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â  Nocturia</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">6</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">Nervous system disorders</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â  Dizziness
    
     <sup>h</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">5</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="top">0.7</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>includes hot flush and flushing 
  <br/>
                           <sup>b</sup>includes hypertension, essential hypertension, and blood pressure increased 
  <br/>
                           <sup>c</sup>includes injection site pain, injection site erythema, injection site hemorrhage, injection site nodule, injection site paraesthesia, injection site pruritus, and injection site warmth 
  <br/>
                           <sup>d</sup>includes fatigue and asthenia 
  <br/>
                           <sup>e</sup>includes upper respiratory tract infection, sinusitis, and nasopharyngitis 
  <br/>
                           <sup>f</sup>includes musculoskeletal pain, back pain, and bone pain 
  <br/>
                           <sup>g</sup>includes micturition urgency and dysuria 
  <br/>
                           <sup>h</sup>includes dizziness, dizziness postural, vertigo, and vertigo positional.

 </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="ss6.2">
                     <id root="2ef88b24-e86a-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of CAMCEVI or leuprolide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse reactions were reported.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Allergic Conditions:</content>Â hypersensitivity reactions including anaphylaxis, rash, urticaria, and photosensitivity reactions

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular System:</content>hypotension, myocardial infarction, pulmonary embolism

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Central/Peripheral Nervous System:</content>convulsion, peripheral neuropathy, spinal fracture/paralysis

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine System:</content>pituitary apoplexy, diabetes

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepato-biliary disorder:</content>drug-induced liver injury

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic:</content>leukopenia

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content>mood swings, including depression, suicidal ideation and attempt

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorder:</content>interstitial lung disease

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal System:</content>decreased bone density, tenosynovitis-like symptoms, fibromyalgia

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous:</content>injection site induration or swelling

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urogenital System:</content>prostate pain

 </paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss8">
               <id root="2ef88b24-e86b-13fa-e063-6294a90ad698"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20240319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Females and males of reproductive potential: CAMCEVI may impair fertility. (
  
     <linkHtml href="#ss8.3">8.3</linkHtml>)
 
    </item>
                           <item>Safety and effectiveness in pediatric patients have not been established. (
  
     <linkHtml href="#ss8.4">8.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ss8.1">
                     <id root="2ef88b24-e86c-13fa-e063-6294a90ad698"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on findings in animal studies and mechanism of action, CAMCEVI can cause fetal harm when administered to a pregnant woman
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#ss12.1">12.1</linkHtml>)].
 
  </content>There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose
 
  <content styleCode="italics">(see data)</content>. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Major fetal malformations were observed in developmental and reproductive toxicology studies in rabbits after a single administration of a monthly formulation of leuprolide administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (approximately 1/1500 to 1/15 the human dose based on body surface area using an estimated daily dose in animals and humans). Since a depot formulation was utilized in the study, a sustained exposure to leuprolide was expected throughout the period of organogenesis and to the end of gestation. Similar studies in rats did not demonstrate an increase in fetal malformations, however, there was increased fetal mortality and decreased fetal weights with the two higher doses of the monthly formulation of leuprolide in rabbits and with the highest dose in rats.</paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
               <component>
                  <section ID="ss8.2">
                     <id root="2ef88b24-e86d-13fa-e063-6294a90ad698"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The safety and efficacy of CAMCEVI have not been established in females. There is no information regarding the presence of leuprolide in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in a breastfed child, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss8.3">
                     <id root="2ef88b24-e86e-13fa-e063-6294a90ad698"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on findings in animals and mechanism of action, CAMCEVI may impair fertility in males of reproductive potential
 
  <content styleCode="italics">[see</content>
                           <content styleCode="italics">Clinical Pharmacology (
  
   <linkHtml href="#ss12.1">12.1</linkHtml>), Nonclinical Toxicology (
  
   <linkHtml href="#ss13.1">13.1</linkHtml>)
 
  </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss8.4">
                     <id root="2ef88b24-e86f-13fa-e063-6294a90ad698"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of CAMCEVI in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss8.5">
                     <id root="2ef88b24-e870-13fa-e063-6294a90ad698"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 137 patients who received CAMCEVI in the FP01C-13-001 study, 74% were 65 years of age or older, while 37% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss11">
               <id root="2ef88b24-e871-13fa-e063-6294a90ad698"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>CAMCEVI is a sterile formulation of leuprolide mesylate for subcutaneous injection. CAMCEVI is designed to deliver approximately 42 mg of leuprolide over 6 months.</paragraph>
                  <paragraph>Leuprolide mesylate is a synthetic nonapeptide analog of naturally occurring GnRH and is a GnRH agonist. The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide mesylate (salt) with the following structural formula. The pH of 50 mg/mL solution of leuprolide mesylate in water is approximately 5.7.</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
                  <paragraph>CAMCEVI is supplied as a kit with a pre-filled, single-dose, sterile syringe for subcutaneous injection. Each pre-filled syringe delivers 42 mg leuprolide (equivalent to approximately 48 mg leuprolide mesylate), poly(D, L-lactide) (184 mg) polymer and
 
  <content styleCode="italics">N</content>-methyl-2-pyrrolidone (136 mg).

 </paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>camcevi-inj-structure-terumo-needle</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="camcevi-inj-structure-terumo-needle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss12">
               <id root="2ef88b24-e872-13fa-e063-6294a90ad698"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250224"/>
               <component>
                  <section ID="ss12.1">
                     <id root="2ef88b24-e873-13fa-e063-6294a90ad698"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Leuprolide, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
               <component>
                  <section ID="ss12.2">
                     <id root="2ef88b24-e874-13fa-e063-6294a90ad698"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Mean serum testosterone concentrations transiently increased, then fell to below castrate threshold levels (â¤ 50 ng/dL) within 3 weeks following administration of the dose of leuprolide, and generally remained below castrate thresholds levels throughout treatment.</paragraph>
                        <paragraph>In humans, subcutaneous administration of single daily doses of leuprolide result in an initial increase in circulating levels of LH and FSH, leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males). However, continuous daily administration of leuprolide results in decreased levels of LH and FSH. In males, testosterone is reduced to below castration levels. These decreases generally occur within 2 to 4 weeks after initiation of treatment, and castration levels of testosterone in prostatic cancer patients have been demonstrated for periods of up to 5 years.</paragraph>
                     </text>
                     <effectiveTime value="20240318"/>
                  </section>
               </component>
               <component>
                  <section ID="ss12.3">
                     <id root="2ef88b24-e875-13fa-e063-6294a90ad698"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Leuprolide concentration is variable, exhibiting an initial rapid increase followed by a rapid decline over the first 3 days before reaching steady concentrations for the duration of the dosing interval. The mean serum leuprolide C
 
  <sub>max</sub>was 94.5 and 99 ng/mL following the first and second doses of CAMCEVI, respectively. The mean serum concentration was maintained at 0.497â2.57 and 0.507â2.39 ng/ml after Day 3 post the first and second doses, respectively. The mean AUC
 
  <sub>0-6 mon</sub>was 224 and 268 day.ng/mL following the first and second doses of CAMCEVI, respectively.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The median T
 
  <sub>max</sub>of leuprolide was 3.2 and 2.1 hours following the first and second doses of CAMCEVI, respectively

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The mean steady-state volume of distribution of leuprolide was 27 L following an intravenous bolus in healthy male volunteers. Protein binding of leuprolide ranged from 43% to 49% in vitro.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean systemic clearance was 7.6 L/h and terminal elimination half-life of approximately 3 hours following an intravenous bolus of leuprolide in healthy male volunteers.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Administration of radiolabeled leuprolide was metabolized to smaller inactive peptides which may then be further catabolized.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Excretion of leuprolide has not been evaluated with CAMCEVI.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the systemic exposure of leuprolide were observed based on age (51 to 88 years), race/ethnicity (White, Black, Asian), or body weight (54 to 134 kg). The effect of renal or hepatic impairment on the pharmacokinetics of leuprolide has not been evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss13">
               <id root="2ef88b24-e876-13fa-e063-6294a90ad698"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250224"/>
               <component>
                  <section ID="ss13.1">
                     <id root="2ef88b24-e877-13fa-e063-6294a90ad698"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Two-year carcinogenicity studies were conducted with leuprolide in rats and mice. In rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose-related increase of pancreatic islet-cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group). In mice, no pituitary abnormalities were observed at a dose as high as 60 mg/kg for 2 years. Patients have been treated with leuprolide for up to 3 years with doses as high as 10 mg/day and for 2 years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.</paragraph>
                        <paragraph>Mutagenicity studies have been performed with leuprolide using bacterial and mammalian systems. These studies provided no evidence of mutagenic potential.</paragraph>
                        <paragraph>Leuprolide may reduce male and female fertility. Administration of leuprolide to male and female rats at doses of 0.024, 0.24, and 2.4 mg/kg as monthly depot formulation for up to 3 months (approximately as low as 1/30 of the human dose based on body surface area using an estimated daily dose in animals and humans) caused atrophy of the reproductive organs, and suppression of reproductive function. These changes were reversible upon cessation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250224"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss14">
               <id root="2ef88b24-e878-13fa-e063-6294a90ad698"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of CAMCEVI was evaluated in an open label, single arm, multinational study FP01C-13-001 (
 
  <linkHtml href="https://clinicaltrials.gov/ct2/show/record/NCT02234115">NCT02234115</linkHtml>) in patients with advanced prostate carcinoma who have a baseline morning serum testosterone level &gt;150 ng/dL and Eastern Cooperative Oncology Group performance status â¤ 2. CAMCEVI was administered subcutaneously at a dose of 42 mg initially on Day 0 and on Week 24.

 </paragraph>
                  <paragraph>The population (n = 137) had a median age of 71 years (range 51 to 88) and was 90% White, 6% Black, and 4% Asian. Disease stage was distributed as follows: 23% metastatic (M1), 27% locally advanced (T3/4 NX M0 or any T N1 M0), 26% localized (T1 or T2 N0 M0), and 24% not classifiable. The median testosterone concentration at baseline was 440 ng/dL.</paragraph>
                  <paragraph>The major efficacy outcome measure was medical castration rate, defined as achieving and maintaining serum testosterone suppression to â¤ 50 ng/dL by Week 4 through Week 48 of treatment. Following the first injection of CAMCEVI, serum testosterone levels were suppressed to â¤ 50 ng/dL by Week 4 (+/-7 days) in 98.5% of the patients; and from Week 4 through Week 48 in 97.0% of patients (95% CI: 92.2-98.9) estimated using the Kaplan-Meier method. The time course of percent change from baseline in testosterone suppression are shown in Figure 1. The percentage of patients with testosterone suppression to â¤ 20 ng/dL was 69.3% on Day 28.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1 CAMCEVI Mean (95% CI) Percentage Change from Baseline in Serum Testosterone Concentration Over Time (N =137)</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM7"/>
                  </paragraph>
                  <paragraph>In the clinical trial, PSA levels were monitored and were lowered on average by 51% after 4 weeks after administration of CAMCEVI, 83% after 3 months and remained suppressed throughout the 48 weeks of treatment. These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline correlates with clinical benefit.</paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>camcevi-inj-figure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="camcevi-inj-figure-1-terumo-needle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ss16">
               <id root="2ef88b24-e879-13fa-e063-6294a90ad698"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>CAMCEVI is a sterile, off-white to pale yellow, viscous and opalescent injectable emulsion supplied in a kit as a single-dose, pre-filled syringe. CAMCEVI is available as follows:</paragraph>
                  <table width="60%" cellspacing="0" cellpadding="0">
                     <col width="500px"/>
                     <col width="450px"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule">
                              <paragraph>Kit Contents</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule">
                              <paragraph>NDC</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule">
                              <paragraph>Injectable emulsion in a pre-filled syringe containing 42 mg leuprolide for subcutaneous injection, a sterile 18-gauge SurGuard
     
      <sup>Â®</sup>3 safety needle, and Prescribing Information.
    
     </paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule" valign="top">
                              <paragraph>69448-023-63</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store CAMCEVI at 2Â°Câ8Â°C (36Â°Fâ46Â°F). Protect CAMCEVI from light by storing in the original package until time of use. Do not freeze or shake.</paragraph>
                  <paragraph>The rubber used in syringe tip cap and plunger stopper is not made of natural rubber latex.</paragraph>
               </text>
               <effectiveTime value="20240319"/>
            </section>
         </component>
         <component>
            <section ID="ss17">
               <id root="2ef88b24-e87a-13fa-e063-6294a90ad698"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that if they have experienced hypersensitivity with other GnRH agonist drugs like CAMCEVI, CAMCEVI is contraindicated
  
   <content styleCode="italics">[see Contraindications (
   
    <linkHtml href="#ss4">4</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Tumor Flare</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that CAMCEVI can cause tumor flare during the first weeks of treatment. Inform patients that the increase in testosterone can cause an increase in urinary symptoms or pain. Advise patients to contact their healthcare provider if uretral obstruction, spinal cord compression, paralysis, or new or worsened symptoms occur after beginning CAMCEVI treatment
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ss5.1">5.1</linkHtml>)]
  
   </content>.
 
  </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Hyperglycemia and Diabetes</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise patients that there is an increased risk of hyperglycemia and diabetes with CAMCEVI therapy. Inform patients that periodic monitoring for hyperglycemia and diabetes is required when being treated with CAMCEVI
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#5.2">5.2</linkHtml>)]
  
   </content>.
 
  </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Cardiovascular Diseases</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that there is an increased risk of myocardial infarction, sudden cardiac death, and stroke with CAMCEVI treatment. Advise patients to immediately report signs and symptoms associated with these events to their healthcare provider for evaluation
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ss5.3">5.3</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">QT/QTc Prolongation</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that CAMCEVI can cause QT/QTc prolongation. Advise patients to immediately contact their healthcare provider in the event of syncope, presyncopal symptoms, or cardiac palpitations
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ss5.4">5.4</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Convulsions</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that there is an increased risk of convulsions with CAMCEVI treatment. Advise patients to immediately contact their healthcare provider if they experience convulsions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ss5.5">5.5</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Injection Site Reactions</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that injection site related adverse reactions may occur such as transient burning/stinging, pain, bruising, and redness. Advise patients to contact their healthcare provider if they experience rash or severe injection site reactions
  
   <content styleCode="italics">[see Adverse Reactions (
   
    <linkHtml href="#ss6.1">6.1</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Urogenital Disorders</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise patients that CAMCEVI may cause impotence.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that CAMCEVI may cause infertility
  
   <content styleCode="italics">[see Use In Specific Populations (
   
    <linkHtml href="#ss8.3">8.3</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>Manufactured for: 
  <br/>  Accord BioPharma Inc. 
  <br/>  8041 Arco Corporate Drive, Suite 200 
  <br/>  Raleigh, NC 27617, USA
 </paragraph>
                  <paragraph>By: 
  <br/>  Fareva Pau 
  <br/>  Fareva Pau 1, Avenue du Bearn, IDRON, 64320, France 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250224"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2ef88b24-e87b-13fa-e063-6294a90ad698"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL -Blister Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM10"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PRINCIPAL DISPLAY PANEL -Blister Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="camcevi-inj-blister-label-terumo-needle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2ef88b24-e87c-13fa-e063-6294a90ad698"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL -Carton Label (front)</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM11"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>PRINCIPAL DISPLAY PANEL -Carton Label(front)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="camcevi-inj-carton-label-terumo-needle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2ef88b24-e87d-13fa-e063-6294a90ad698"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL -Carton Label (back)</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM12"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <component>
                  <observationMedia ID="MM12">
                     <text>PRINCIPAL DISPLAY PANEL -Carton Label (back)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="camcevi-inj-carton-label-1-terumo-needle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2ef88b24-e87e-13fa-e063-6294a90ad698"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL -Syringe Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM13"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240319"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>PRINCIPAL DISPLAY PANEL -Syringe Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="camcevi-inj-syringe-label-terumo-needle.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>